Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

FDA publishes final industry guidance for CAR-T and gene therapies

The new guidance can also be applied to other genetically modified lymphocyte products, including  CAR NK cells

- PMLiVE

Researchers identify five rare cases of Alzheimer’s from historic medical treatments

The study found that c-hGH treatment transmitted the amyloid-beta protein, a hallmark of AD

- PMLiVE

PM Society Awards tickets now on sale!

The 38th PM Society Awards will take place on Friday 15 March in London

- PMLiVE

Top pharma trends and predictions for 2024

Looking at the role Gen AI and cutting-edge digital platforms will play in healthcare over the coming year

- PMLiVE

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN X Health launches to provide data-driven creativity to the pharmaceutical industry

OPEN Health

- PMLiVE

GSK partners with DNA specialist Elegen to advance medicines and vaccines

GSK will leverage Elegen’s cell-free synthetic DNA production technology

- PMLiVE

Takeda’s HyQvia receives EC approval for rare neuromuscular disorder CIDP

HyQvia can now be used as a maintenance therapy for patients of all ages with CIDP

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Study suggests simple blood test could spare brain cancer patients risky surgery

The TriNetra-Glio test isolates broken-free tumour cells from the circulating tumour in the blood

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

The secret of the superhuman is you (and AI)

Unlocking future-readiness with three essential human skills

- PMLiVE

GSK’s Omjjara approved by EC to treat myelofibrosis patients with anaemia

About 40% of myelofibrosis patients have moderate-to-severe anaemia at the time of diagnosis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links